Development of a bispecific antibody tetramerized through hetero-associating peptides

FEBS Journal

Volumn 282, Issue 22, 2015, Pages 4389-4401

  Osaki, Tomohiro ^a   Fujisawa, Shingo ^a   Kitaguchi, Masahiro ^a   Kitamura, Masaya ^a   Nakanishi, Takeshi ^a  

^a Osaka Prefecture University   (Japan)

Author keywords

bispecific antibody; cancer therapy; CD16; epidermal growth factor receptor; self associating peptide

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR;

CELL CULTURE; CHEMISTRY; CYTOTOXICITY; HUMAN; IMMUNOLOGY; NATURAL KILLER CELL; PROTEIN MULTIMERIZATION; SURFACE PLASMON RESONANCE;

ANTIBODIES, BISPECIFIC; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; PROTEIN MULTIMERIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; SURFACE PLASMON RESONANCE;

EID: 84954527495     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13505     Document Type: Article

References (46)

1. Campbell J, Lowe D, &, Sleeman MA, (2011) Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol 162, 1470-1484.
2. Tassev DV, &, Cheung NK, (2009) Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 9, 341-353.
3. Boder ET, &, Jiang W, (2011) Engineering antibodies for cancer therapy. Annu Rev Chem Biomol Eng 2, 53-75.
4. Chames P, &, Baty D, (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1, 539-547.
5. Choudhary S, Mathew M, &, Verma RS, (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16, 495-503.
6. List T, &, Neri D, (2013) Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 5, 29-45.
7. ®) antibody construct blinatumomab as a potential therapy. Int Immunol 27, 31-37.
8. Lameris R, de Bruin RC, Schneiders FL, van Bergen En Henegouwen PM, Verheul HM, de Gruijl TD, &, van der Vliet HJ, (2014) Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 92, 153-165.
9. ™) molecule. MAbs 5, 358-363.
10. Kostelny SA, Cole MS, &, Tso JY, (1992) Formation of a bispecific antibody by the use of leucine zippers. J Immunol 148, 1547-1553.
11. Zhu X, Wang L, Liu R, Flutter B, Li S, Ding J, Tao H, Liu C, Sun M, &, Gao B, (2010) COMBODY: one-domain antibody multimer with improved avidity. Immunol Cell Biol 88, 667-675.
12. Rossi EA, Goldenberg DM, &, Chang CH, (2012) The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 23, 309-323.
13. Asano R, Nakayama M, Kawaguchi H, Kubota T, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al,. (2012) Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system. FEBS J 279, 223-233.
14. Doerks T, Bork P, Kamberov E, Makarova O, Muecke S, &, Margolis B, (2000) L27, a novel heterodimerization domain in receptor targeting proteins Lin-2 and Lin-7. Trends Biochem Sci 25, 317-318.
15. Arbabi-Ghahroudi M, Desmyter A, Wyns L, Hamers R, &, Muyldermans S, (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414, 521-526.
16. Lee S, Fan S, Makarova O, Straight S, &, Margolis B, (2002) A novel and conserved protein-protein interaction domain of mammalian Lin-2/CASK binds and recruits SAP97 to the lateral surface of epithelia. Mol Cell Biol 22, 1778-1791.
17. Roh MH, Makarova O, Liu CJ, Shin K, Lee S, Laurinec S, Goyal M, Wiggins R, &, Margolis B, (2002) The Maguk protein, Pals1, functions as an adapter, linking mammalian homologues of Crumbs and Discs Lost. J Cell Biol 157, 161-172.
18. Li Y, Karnak D, Demeler B, Margolis B, &, Lavie A, (2004) Structural basis for L27 domain-mediated assembly of signaling and cell polarity complexes. EMBO J 23, 2723-2733.
19. Sowdhamini R, Srinivasan N, Shoichet B, Santi DV, Ramakrishnan C, &, Balaram P, (1989) Stereochemical modeling of disulfide bridges. Criteria for introduction into proteins by site-directed mutagenesis. Protein Eng 3, 95-103.
20. Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, &, Koizumi F, (2014) KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 134, 2146-2155.
21. Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang TA, Durocher Y, Trojahn U, Baardsnes J, Jaramillo ML, Li S, Baral TN, et al,. (2010) Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett 289, 81-90.
22. Deyev SM, Waibel R, Lebedenko EN, Schubiger AP, &, Plückthun A, (2003) Design of multivalent complexes using the barnase·barstar module. Nat Biotechnol 21, 1486-1492.
23. HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 281, 35186-35201.
24. Kazane SA, Axup JY, Kim CH, Ciobanu M, Wold ED, Barluenga S, Hutchins BA, Schultz PG, Winssinger N, &, Smider VV, (2013) Self-assembled antibody multimers through peptide nucleic acid conjugation. J Am Chem Soc 135, 340-346.
25. L) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 422, 259-264.
26. H2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel 25, 603-612.
27. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, &, Alvarez-Vallina L, (2010) Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 28, 355-362.
28. Brennan M, Davison PF, &, Paulus H, (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Sience 229, 81-83.
29. Suresh MR, Cuello AC, &, Milstein C, (1986) Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol 121, 210-228.
30. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, &, Chang CH, (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 103, 6841-6846.
31. Feng W, Long JF, &, Zhang M, (2005) A unified assembly mode revealed by the structures of tetrameric L27 domain complexes formed by mLin-2/mLin-7 and Patj/Pals1 scaffold proteins. Proc Natl Acad Sci USA 102, 6861-6866.
32. Asano R, Kumagai T, Nagai K, Taki S, Shimomura I, Arai K, Ogata H, Okada M, Hayasaka F, Sanada H, et al,. (2013) Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel 26, 359-367.
33. Holliger P, &, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23, 1126-1136.
34. + tumor cells. MAbs 6, 728-739.
35. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, &, de Haas M, (1997) Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90, 1109-1114.
36. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, &, Watier H, (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754-758.
37. Weng WK, &, Levy R, (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21, 3940-3947.
38. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al,. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26, 1789-1796.
39. Turini M, Chames P, Bruhns P, Baty D, &, Kerfelec B, (2014) A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget 5, 5304-5319.
40. Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K, &, Yamamura K, (1989) Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 79, 269-277.
41. Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al,. (2010) Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 277, 477-487.
42. Behar G, Sibéril S, Groulet A, Chames P, Pugnière M, Boix C, Sautès-Fridman C, Teillaud JL, &, Baty D, (2008) Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 21, 1-10.
43. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, &, van Bergen en Henegouwen PM, (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 56, 303-317.
44. Shishido T, Azumi Y, Nakanishi T, Umetsu M, Tanaka T, Ogino C, Fukuda H, &, Kondo A, (2009) Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. J Biochem 146, 867-874.
45. Els Conrath K, Lauwereys M, Wyns L, &, Muyldermans S, (2001) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276, 7346-7350.
46. Goldstein NI, Prewett M, Zuklys K, Rockwell P, &, Mendelsohn J, (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1, 1311-1318.